

# Commercial PA Criteria Effective: April 20, 2020

### Prior Authorization: Ketoprofen

**Products Affected:** ketoprofen 25mg capsule, ketoprofen 200mg extended release oral capsules, Kiprofen 25mg capsule

**Medication Description:** Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. The anti-inflammatory, analgesic, and antipyretic properties of ketoprofen have been demonstrated in classical animal and in vitro test systems. In anti-inflammatory models ketoprofen has been shown to have inhibitory effects on prostaglandin and leukotriene synthesis, to have antibradykinin activity, as well as to have lysosomal membrane-stabilizing action. However, its mode of action, like that of other nonsteroidal anti-inflammatory drugs, is not fully understood.

### Covered Uses:

*Ketoprofen 200mg extended release oral capsules*: Management of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

*Ketoprofen 25mg capsules & Kiprofen 25mg capsules*: Management of signs and symptoms of osteoarthritis and rheumatoid arthritis, pain, and treatment of primary dysmenorrhea.

#### Exclusion Criteria:

- 1. Patients with asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- 2. In the setting of coronary artery bypass graft (CABG) surgery
- 3. Hypersensitivity to ketoprofen

### **Required Medical Information:**

- 1. Diagnosis
- 2. Medical History
- 3. Previous therapies tried and failed

Age Restrictions: 18 years of age and older

### Prescriber Restrictions: N/A

### Coverage Duration: 12 months

### **Other Criteria:**

### Ketoprofen 200mg extended release capsules

- A. Patient has a diagnosis of rheumatoid arthritis OR osteoarthritis; AND
- B. Patient has had a trial and failure, intolerance, or contraindication to ALL the following generic NSAIDs: diclofenac potassium/sodium (oral), etodolac IR/ER, ibuprofen (Rx), meloxicam, nabumetone, naproxen (Rx), celecoxib.

March 22, 2024





## Ketoprofen 25mg capsules & Kiprofen 25mg Capsules

- A. Patient has one of the following conditions:
  - i. Rheumatoid arthritis
  - ii. Osteoarthritis
  - iii. Pain
  - iv. Primary dysmenorrhea; AND
- B. Patient has had a trial and failure, intolerance, or contraindication to ALL the following generic NSAIDs: diclofenac potassium/ sodium (oral), etodolac IR/ER, ibuprofen (Rx), meloxicam, nabumetone, naproxen (Rx), celecoxib.

### References:

- 1. Product Information: ketoprofen oral capsules, oral extended release capsules, ketoprofen oral capsules, oral extended release capsules. Mylan Pharmaceuticals Inc. (per DailyMed), Morgantown, WV, 2011.
- 2. Facts & Comparisons online

Policy Revision history	

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	4/20/2020
2.	Update	Ketoprofen 200mg extended release capsules added to Policy PA criteria added for Ketoprofen 200mg extended release capsules	Products Affected Covered Uses Other Criteria	10/1/2020
3.	Update	Updated Other criteria for both Ketoprofen 200mg and 25mg from requiring at least TWO trials to All of the listed generic trials	Other Criteria	12/3/2020
4	Update	Addition of Kiprofen	Products Affected Covered Uses Other Criteria	03/22/2024

